Johnson & Johnson developing stem cell cure for Type 1 diabetes – The Week Magazine
Xconomy |
Johnson & Johnson developing stem cell cure for Type 1 diabetes
The Week Magazine Johnson & Johnson and biotech company ViaCyte are exploring a possible cure for Type 1 diabetes with encouraging results, The Associated Press reports. The stem cell treatment involves turning embryotic stem cells into insulin-producing cells in a lab … ViaCyte Reports on Stem Cell Diabetes Trial, Absorbs BetaLogics Johnson and Johnson Testing Stem Cell Treatment for Type 1 Diabetes ViaCyte Acquires Rights to BetaLogics Assets, Expanding and Extending Industry-Leading Portfolio for Stem Cell … |
